

Docket No.: 050193-0109



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Customer Number: 20277

Salah D. KIVLIGHN, et al. : Confirmation Number: 4997

Application No.: 09/892,505 : Group Art Unit: 1636

Filed: June 28, 2001 : Examiner: NGUYEN, QUANG

For: TREATMENT FOR CARDIOVASCULAR DISEASE

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Each non-English language reference was first cited in a corresponding foreign application search report or office action and its relevance discussed therein. A copy of the

09/892,505

foreign search report or office action, together with an English language version thereof, is attached for the Examiner's information.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MeDERMOTT WILL & EMERY LLP

Judith L. Toffenetti Registration No. 39,048

600 13th Street, N.W. Washington, DC 20005-3096 Phone: 202.756.8000 JLT:gav

Facsimile: 202.756.8087 **Date: March 23, 2005**

Please recognize our Customer No. 20277 as our correspondence address.



SHEET 1 OF 1

| INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) | | | | | ATTY. DOCKET NO. 050193-0109 | SERIAL NO. 09/892,505 | | | | | |
|--|---|--|---|--------------------------------|-------------------------------------|--|-----------|-----|---|--|--|
| | | | | | APPLICANT Salah D. KIVLIGHN, et al. | | | | | | |
| | | | | | FILING DATE June 28, 2001 | GROUP 1636 | | | | | |
| | | | U | .S. PATEN | T DOCUMENTS | | | | | | |
| EXAMINER'S INITIALS | CITE NO. | Document Number Number-Kind Code2 (# known) | | Publication Date MM-DD-YYYY | | Name of Patentee or Applicant of Cited Document | | | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | |
| | | US | | | | | ļ <u></u> | | | | |
| | | US | | | | | <u> </u> | | | | |
| | | US | | | | | | | | | |
| | <u> </u> | US | | | | | <u> </u> | | | | |
| | l | US | | | | | | | | | |
| | | US | | | | | 1 | | | | |
| | | US | | | | | | | · | | |
| | | υs | | | | | | | | | |
| | | US | | | | | | | | | |
| | | US | | | | | | | | | |
| | | US | | | | | ļ | | | | |
| | | US | | | | | | | | | |
| | <u> </u> | US | | EODEIGN DA | TENT DOCUMENTS | | <u> </u> | | | | |
| EXAMINER'S | ı | Fo | reign Patent Document | Publication Date | | Pages, Colum | ns Lines | Tra | nslation | | |
| INITIALS | CITE NO. | | intry Codes -Number 4 -Kind Codes (if known) | MM-DD-YYYY | Applicant of Cited Document | Where Relevant Figures Appear | | Yes | No | | |
| | | | GB 1 451 029 | 09/29/1976 | MERCK & CO. INC. | | | Х | | | |
| | | | EP 0 337 350 A2 | 10/18/1989 | EISAI CO., LTD. | | | Х | | | |
| | | ├ ─ | | | | | | | | | |
| | | \vdash | | | | | | | | | |
| | | \vdash | | | | | | | | | |
| | · | | | | or, Title, Date, Pertinent Pages, E | | | | | | |
| EXAMINER'S Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine | | | | | | | | | | | |
| INITIALS | NITIALS CITE journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | | | | | | |
| | MIYAMOTO, Y., et al. "Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors.", Proceedings of the Society for Experimental Biology and Medicine, April 1996, Volume 211, NR 4, PG 366-373 | | | | | | | | | | |
| | | | | | | | | | | | |
| EXAMINER | | | | | - 1 1 | DATE CONSIDERED | | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.